Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PUR1900 FDA Type C Results, LPAD / EUA ???
FEND Government Contracts ??
PUR1800 Repurposed ??
PUR1900 Reformulations / Combinations ??
Nob Hill Therapeutics ??
Siwa Therapeutics ??
This was apart of the 20M share/$40M direct offering at $2.00.
Most direct offerings have warrants attached. This one did not. It was essentially a market buy of 20M shares at $2.00.
Very bullish.
$PULM
Nothing JnJ related was discussed during this JnJ Webinar.
Doesn't look like iSPERSE is going to be w/in this conversation.
Aye -- looks like Barda is interested in Micro-Array patches for Vaccines.
Yes webinar starts in an hour. They are suppose to talk about 'current things' -- let's hear about iSPERSE. This would be the perfect event for such to be talked about.
Fully diluted and the number is closer to 75%
Expecting big news on PUR1800 -- used for COVID-19? I think so.
Also thinking JnJ / Pulmatrix are involved inhaled vaccine.
$PULM
"Developing Alternative Administration Techniques for Therapeutics & Vaccines" -- Johnson and Johnson Webinar, 2/23
iSPERSE Involved?
https://alternativeadministration.splashthat.com/?toid=9450359&p=3877d0bad9b7a4475c09db8bc6b0f53fc11cf61884d816f1c0ea33e97855032b2c48e7bb&guest-access-hash=NDU4MDI3OTE2fDM3MzY3NjgyN3wxNjEzNDc0MzkxOzUxZTRkYWRiYzYzMzA0ODA4ZjUxZjc0YjdiMjQ5ZGU5NzczM2E0OTViNTkwNDdkNmQzNmUwOWYyMmU0ZTBhMjQ=
$PULM
Welcome!
$PULM
Yes, a very good investment. Nice add today.
$PULM
I think the Total O/S is 86M, with the 20M new direct offering shares.
75-80% insiders, institutions, and employee owned total outstanding shares here.
$PULM
Yep!
I am doing quite well . News pending, $10+ coming first.
$PULM
PULM Pipeline:
Pulmazole (PUR1900) for ABPA Phase 3 coming soon/imminently! Possible treatments for other indications as well! EUA for Covid related/increased ABPA, but more speculative at the moment. $CIPLA, their partner, #1 inhalation player in India
PUR1800 P1/B trials restarting during Q1 2021. PUR1800 also treats Cytokine storms (covid) as well as COPD... and is apart of 3 molecule set $JNJ bought from Respivert licensed to Pulmatrix. More wildcards (inhaled vaccine) could happen with this partnership in a flash.
FEND (PUR003) is the answer to the question people don't know to ask. 2 facemasks , really? How about airway hygiene through misted calcium-rich saline-water. Will become as common as soap in years time.
PUR3100 entering the migraine space, who's their partner/target drug reformulation? One of the leading players? Such will open the door to all sorts of non-respiratory indications.
Oh, and Nocion just raised $15M-- looks like they are ramping up.
And $75M Cash, No Debt
$PULM
Good choice, major news within next 2 weeks, imo.
$PULM
Going up from $2.00.
$PULM
Snoozefest on this message board; considering we going to $100+
$PULM
$100+ coming in 2021
$PULM
Big time news coming. Global mania coming.
PT $100+
$PULM
Wake up folks
$PULM
$PULM
Q1 2021 at the latest. Tomorrow at the earliest. JnJ just filed for their FDA EUA -- wonder if iSPERSE is involved in their Gen 2 inhaled version.
Pulmazole going to be a big winner. FDA Type C meeting results = P3 & EUA (potential)?
$PULM
it's coming... options are being cashed in right now! Hedge Funds & the CEO.
$PULM
My end of 2021 Price Target: $100++
$PULM
"Changing Medicine with a new generation of inhaled pulmonary-delivered Therapeutics"
...iSPERSE™ is a scalable platform, with application across drug classes and dry-powder delivery devices. This creates broad potential for pipeline development and strategic partnership.
... Provided about 50-fold higher lung exposure and 80-fold lower plasma exposure than Sporanox, at 1/10th the dose
... iSperse™ has the ability to deliver 3x the effective lung dose versus the lactose blend formulation of the active ingredient while improving the safety margin
... This partnership leverages the origins of PULMATRiX as a biodefense company and its intellectual property to help combat rapidly emerging global pandemics
$PULM
Current Partners:
1)Johnson and Johnson - largest pharma company in the world
2)Cipla, 2nd largest pharmaceutical company in India, largest inhalation pharmaceutical company in India
3)Nocion Therapeutics -- with former Pulmatrix/iSPERSE developers now CEO & VP Pharmaceutical Development over there
4)Sensory Cloud -- with former Pulmatrix co-founder & lead developer of iSPERSE , David Edwards
5)Board of Directors/Clinical Advisory Board: Leading global experts in associated fields, premier organizations
Then factor in Moderna founder, and most cited engineer in history with MIT labs named after him, Robert Langer -- who was also a co-founder of Pulmatrix/iSPERSE -- and is an active promoter of FEND!
Throw in DARPA research grants, FEND being created in response to homeland security asking for potential solutions against bio-warfare, and the setup which Pulmatrix has positioned themselves in -- and that my friends is the basis for due diligence.
An epic story unfolding here.
$PULM
$PULM --- iSPERSE, The Next Generation of Inhaled Medicine
Pulmazole (PUR1900), an iSPERSE Enabled Inhaled Itraconazole, Phase 3/EUA coming out as a result of the FDA-Type C Meeting? Pulmatrix CEO, Ted Raad, was on the original commercial launch team of Itraconazole (Sporanox) 25+ years ago.
And what about PUR1800, an iSPERSE enabled inhaled Kinase Inhibitor (RV1168) -- which may become a leader in the cytokine storm therapeutics space as well as COPD (unbelievably huge) -- partnered with
$JNJ
And FEND (PUR003/PUR006) may have anti-inflammatory/asthma benefits in addition to being a prophylactic bio-aerosol reducer -- b/c of the delivery method of misted salt? Could
$MRNA get involved here?
Nocion studying cough therapeutics... they will seek to adopt iSPERSE to deliver their charged particles in the upcoming future.
And whose our newest partner in the Migraine space with PUR3100?
Oh.. and inhaled vaccines/therapeutics? A company whose premise is centered around best in class inhaled delivery vehicle has never been so valuable.
All imo.
$PULM Short Term Catalysts (anytime now-Q1 2021)
1) PUR1900 FDA Type C Meeting -- likely bullish news coming out of there regarding P3 Trial Setup with Cipla -- perhaps even EUA but speculation only on such comment
2) PUR1900 new updated contract terms with CIPLA (more favorable to Pulmatrix assumed, likely retain US + Europe rights)
2) FEND New Studies/Data & Pathway to Global Launch -- India Manufacturing Pathway -- Potential Partnership with larger manufacturing partners/world organizations
3) PUR1800 Update with J&J - COPD Trials Start
4) Potential wildcard of JnJ inhaled vaccine development utilizing iSPERSE-- and/or other companies such as Pfizer/AstraZeneca (speculative comment yet foundation exists)
5) PUR3100 Migrane pre-clinical design update -- including who we are partnered with in such endeavor...
6) Nocion update of using iSPERSE on any of their portfolio
7) Unexpected partnerships/licensing deals either via therapeutic or vaccine(s) with iSPERSE enabled version